Reuters reported that FDA CDER chief Tracy Beth Høeg is expected to leave the agency following Commissioner Marty Makary’s resignation. Høeg had been acting CDER director after the departure of veteran oncologist Richard Pazdur, and the report cites internal planning leading to a likely exit. The leadership turnover is expected to add uncertainty to CDER operations and program priorities. The report also describes broader staffing efforts within HHS and the White House aimed at changing agency leadership following Makary’s exit, with potential implications for how drug regulation proceeds in the near term.